Terms: = Breast cancer AND KAT6A
10 results:
1. HATS off to kat6a/B inhibitors: A new way to target estrogen-receptor-positive breast cancer.
Jeselsohn R; Polyak K
Cell Chem Biol; 2023 Oct; 30(10):1183-1185. PubMed ID: 37863030
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of a highly potent, selective, orally bioavailable inhibitor of kat6a/B histone acetyltransferases with efficacy against kat6a-high ER+ breast cancer.
Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
[TBL] [Abstract] [Full Text] [Related]
3. Zinc finger and SCAN domain-containing protein 18 is a potential DNA methylation-modified tumor suppressor and biomarker in breast cancer.
Wang Y; Luo Y; Fu S; He L; Pan G; Fan D; Wen Q; Fan Y
Front Endocrinol (Lausanne); 2023; 14():1095604. PubMed ID: 37223020
[TBL] [Abstract] [Full Text] [Related]
4. In Silico Study on the Interactions, Molecular Docking, Dynamics and Simulation of Potential Compounds from
Deshpande SH; Muhsinah AB; Bagewadi ZK; Ankad GM; Mahnashi MH; Yaraguppi DA; Shaikh IA; Khan AA; Hegde HV; Roy S
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770785
[TBL] [Abstract] [Full Text] [Related]
5. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative breast cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract] [Full Text] [Related]
6. kat6a Acetylation of SMAD3 Regulates Myeloid-Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Triple-Negative breast cancer.
Yu B; Luo F; Sun B; Liu W; Shi Q; Cheng SY; Chen C; Chen G; Li Y; Feng H
Adv Sci (Weinh); 2021 Oct; 8(20):e2100014. PubMed ID: 34392614
[TBL] [Abstract] [Full Text] [Related]
7. kat6a, a novel regulator of β-catenin, promotes tumorigenicity and chemoresistance in ovarian cancer by acetylating COP1.
Liu W; Zhan Z; Zhang M; Sun B; Shi Q; Luo F; Zhang M; Zhang W; Hou Y; Xiao X; Li Y; Feng H
Theranostics; 2021; 11(13):6278-6292. PubMed ID: 33995658
[No Abstract] [Full Text] [Related]
8. Concentration Dependence of the Unbound Partition Coefficient Kp
Trünkle C; Lechner C; Korr D; Bouché L; Barak N; Fernández-Montalván A; Süssmuth RD; Reichel A
Drug Metab Dispos; 2020 Jul; 48(7):553-562. PubMed ID: 32357973
[TBL] [Abstract] [Full Text] [Related]
9. Metagenomic characterization of lysine acetyltransferases in human cancer and their association with clinicopathologic features.
Jiang Y; Guo X; Liu L; Rode S; Wang R; Liu H; Yang ZQ
Cancer Sci; 2020 May; 111(5):1829-1839. PubMed ID: 32162442
[TBL] [Abstract] [Full Text] [Related]
10. kat6a, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract] [Full Text] [Related]
